The worldwide risk of contracting the Dengue virus continues into the second half of 2022. As a result, the U.S. Centers for Disease Control and Prevention (CDC) recently reissued various Level 1 Practice Usual Precautions advisories to notify international travelers.
On August 9, 2022, the U.S. CDC issued advisories for dengue risks in Asia, the Pacific Islands, Africa, the Middle East, and the Americas.
The CDC says the countries listed in these advisories report higher-than-usual numbers of dengue cases, and travelers visiting these countries may be at increased risk.
And in the USA, 183 dengue cases have been reported this year, and Puerto Rico has confirmed 128 dengue cases in 2022.
Dengue can become severe within a few hours.
The CDC says that severe dengue is a medical emergency, usually requiring hospitalization.
In severe cases, health effects can include hemorrhage, shock, organ failure, and death.
Because mosquito bites spread dengue, all travelers to risk areas should prevent mosquito bites by using an EPA-registered insect repellent, wearing long-sleeved shirts and long pants when outdoors, and sleeping in an air-conditioned room or room with window screens or under an insecticide-treated bed net.
While the U.S. FDA and other countries have approved the Dengvaxia vaccine, its utility is limited given pre-vaccination diagnostic testing requirements.
Dengvaxia (CYD-TDV) is a live attenuated tetravalent chimeric vaccine made using recombinant DNA technology.
Additional dengue vaccine information is posted at Vax-Before-Travel.com/Dengue.